Rapid Induction of Sarcomas in Rats by Combination of Nickel Sulfide and 3,4-Benzpyrene

Ronald M. Maenza, Arun M. Pradhan, and F. William Sunderman, Jr.

Departments of Pathology R. M. M. and Laboratory Medicine A. M. P., F. W. S./, University of Connecticut Health Center, Farmington, Connecticut 06032

SUMMARY

The interval between administration of carcinogen and development of sarcomas was significantly shorter in males than females. Fischer rats that received bilateral injections into thigh muscles of a combination of 10 mg of Ni₃S₂ and 5 mg of 3,4-benzpyrene (Group C) than in rats that received only 10 mg of Ni₃S₂ (Group A) or only 5 mg of 3,4-benzpyrene (Group B). No sarcomas developed in control rats (Group D), which received only the injection vehicle (penicillin suspension). The period between injection of carcinogens and death from sarcoma averaged 24 ± 5 weeks in Group C versus 26 ± 5 weeks in Group A and 31 ± 10 weeks in Group B (p < 0.001). The proportion of primary sarcomas which were classified as rhabdomyosarcomas was 91% in Group C versus 81% in Group A and 13% in Group B. This study furnishes (a) additional support for speculations concerning carcinogenic interaction between nickel compounds and polycyclic aromatic hydrocarbons and (b) a rapid and convenient experimental technique for inducing rhabdomyosarcomas in rats. This technique is well adapted for use as a laboratory exercise in neoplasia for pathology students.

INTRODUCTION

In 1962, Gilman (6) reported that i.m. administration of nickel sulfide, Ni₃S₂, to rats results in the development of rhabdomyosarcomas. Subsequent studies have confirmed Gilman's observation and have elucidated the effects of (a) the dosage of Ni₃S₂ (7, 13, 17); (b) the physical form of Ni₃S₂ (8); (c) the age, sex, and strain of the rats (2, 15); and (d) various endocrine factors (14, 16, 18) upon the latent period and the incidence of the sarcomas. The biological characteristics of rhabdomyosarcomas which are induced in rats by injection of Ni₃S₂ have been reviewed in previous papers from our laboratory (25, 26). This study has been performed to ascertain whether or not the latent period for development of rat sarcomas can be shortened by combined administration of Ni₃S₂ together with 3,4-benzpyrene, a carcinogen which generally produces fibrosarcomas in rats following i.m. or s.c. administration (1, 3, 5, 10–12, 20, 21).

MATERIALS AND METHODS

The experimental animals were male rats of the Fischer strain (Charles River Breeding Laboratories, North Wilmington, Mass.), maintained on Purina laboratory rat chow. The rats were 8 to 9 weeks old at time of injection. The carcinogens were nickel sulfide powder, Ni₃S₂ (supplied by J. P. W. Gilman, University of Guelph, Guelph, Ontario, Canada), and 3,4-benzpyrene powder (Mann Research Laboratories, Inc., New York, N. Y.). The mean particle diameters of the Ni₃S₂ and 3,4-benzpyrene powders were approximately 2 and 20 μm, respectively, as estimated by electron microscopy. The Ni₃S₂ powder was free from detectable contamination with other metals, as verified by emission spectrographic analysis. In a test for purity, the 3,4-benzpyrene powder was dissolved in hexane:acetone (3:1, v/v), and subjected to thin-layer chromatography on Silica Gel G, with a solvent system of hexane saturated with N,N'-dimethylformamide. The 3,4-benzpyrene migrated as a single fluorescent spot. The injection vehicle was penicillin G procaine suspension, 300,000 units/ml (Wyeth Laboratories, Inc., Philadelphia, Pa.). Suspensions of the carcinogens were prepared as follows: Suspension a, 20 mg of Ni₃S₂/ml of vehicle; Suspension b, 10 mg of 3,4-benzpyrene per ml of vehicle; and Suspension c, 20 mg of Ni₃S₂ + 10 mg of 3,4-benzpyrene per ml of vehicle. Fifty rats in each of 3 experimental groups (A, B, C) were given bilateral injections into the thigh muscles of Suspensions a, b, and c, respectively; 30 rats in a control group (D) were given bilateral injections of the vehicle, alone. The 120 rats all received the injections on a single day. The injections were all made deep into the extensor musculature at the midlength of the thighs (0.5 ml/injection site). No acute mortality, morbidity, or severe local inflammatory reactions occurred in any of the rats.

Physical examinations of the rats were performed each week by an animal caretaker who is skilled in detecting muscle tumors and in gauging the progression of tumor growth. Rats in experimental Groups A, B, and C either died spontaneously or were killed when their tumors became so large that the rats...
could not move about their cages and hence could not obtain food or water. Rats in the control group, D, were all killed at 104 weeks after injection (ages, 112 to 113 weeks). All rats were autopsied, and the tissues were examined by light microscopy. The classification of sarcomas was based upon the histological criteria of Stout and Lattes (23).

Electron microscopy was performed upon sarcomas from 4 or 5 rats in each of the experimental groups. Portions of the tumors were diced in cacodylate-buffered p-formaldehyde at 0 to 4°C and postfixed in s-collidine-buffered 2% OsO4. The tissues were embedded, sectioned, and stained as described by Goldblatt et al. (9). The grids were examined by use of a Phillips 300 electron microscope at 60 kV.

Transplantations were performed with sarcomas from 3 rats in each of the experimental groups. Portions from the margin of each tumor (approximately 0.5 g) were diced in 5 ml of sterile 0.85% NaCl solution (0.85 g/dl), and the tissue was fragmented by repeated forceful aspiration and expulsion with a 5-ml syringe. The cell suspensions were rapidly adjusted to contain approximately 1 X 10⁴ cells/ml, and 0.5 ml of each suspension was injected unilaterally into the thigh musculature of 2 or 3 male Fischer rats, age 8 weeks. The 23 rats that received tumor implants were examined 3 times each week. These rats either died spontaneously or they were killed when their tumors became so large that they were unable to move. The rats were autopsied, and the tissues were examined by light microscopy.

RESULTS

The rats were autopsied, and the tissues were examined by light microscopy. The results of the study are given in Tables 1 and 2. The rats in the experimental groups (A, B, and C) all died with either rhabdomyosarcomas or fibrosarcomas which developed at the sites of the injections. The longest survival was 61 weeks after injection (range, 5 to 9 days), and the recipient rats transplanted tumors were first palpated at an average of 7 days after implantation (range, 5 to 9 days), and the recipient rats were all killed at 104 weeks after the injection of the vehicle. Two benign tumors were found in these control rats: an adrenal adenoma in 1 rat and a s.c. lipoma in the flank of another rat. No malignant tumors were found in any of the control rats.

In their histological and biological characteristics, the sarcomas which developed in Group C (Ni₃S₂ + 3,4-benzpyrene) closely resembled the sarcomas in Group A (Ni₃S₂ alone) and generally differed from the sarcomas in Group B (3,4-benzpyrene alone). Thus, 42 of 46 sarcomas (91%) in Group C were classified histologically as rhabdomyosarcomas compared with 34 of 42 (81%) in Group A and only 5 of 39 (13%) in Group B. Metastases of the sarcomas to lungs or mediastinal lymph nodes were present in 16 of 30 rats (53%) in Group C, compared with 17 of 30 rats (57%) in Group A or only 6 of 30 rats (20%) in Group B (Fig. 5). In general, the presence of distant metastases was associated with sarcomas which were classified histologically as rhabdomyosarcomas, although 2 typical fibrosarcomas in Group B were metastatic to the lung.

The mean latent period (interval between injection of carcinogens and initial palpation of a tumor at an injection site) was significantly shorter in Group C (18 ± 3 weeks) than in either Groups A or B (26 ± 5 and 31 ± 10 weeks, respectively, p < 0.001). The mean survival time (interval between injection of carcinogens and death) was significantly shorter in Group C (24 ± 5 weeks) than in Groups A or B (33 ± 5 and 41 ± 11 weeks, respectively, p < 0.001). The mean interval between initial palpation of tumor and death was 6 ± 3 weeks in Group C, compared with 7 ± 3 in Group A (p < 0.05) and 10 ±5 in Group B (p < 0.001).

Seven rhabdomyosarcomas and 2 fibrosarcomas were transplanted into a total of 23 recipients. Pleomorphic sarcomas similar to that shown in Fig. 6 developed in all of the recipients at the sites of injection. The transplanted tumors grew much more rapidly than the primary tumors. The transplanted tumors were first palpated at an average of 7 days after implantation (range, 5 to 9 days), and the recipient rats

<table>
<thead>
<tr>
<th>Experimental group</th>
<th>Carcinogen</th>
<th>Rats with sarcomas (%)</th>
<th>Rats with rhabdomyosarcomas (%)</th>
<th>Rats with bilateral primary sarcomas (%)</th>
<th>Proportion of primary sarcomas classified as rhabdomyosarcomas (%)</th>
<th>Rats with distant metastases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Ni₃S₂</td>
<td>100 (30/30)</td>
<td>80 (24/30)</td>
<td>40 (12/30)</td>
<td>81 (34/42)</td>
<td>57 (17/30)</td>
</tr>
<tr>
<td>B</td>
<td>3,4-BP</td>
<td>100 (30/30)</td>
<td>13 (4/30)</td>
<td>30 (9/30)</td>
<td>13 (5/39)</td>
<td>20 (6/30)</td>
</tr>
<tr>
<td>C</td>
<td>Ni₃S₂ + 3,4-BP</td>
<td>100 (30/30)</td>
<td>93 (28/30)</td>
<td>p &lt; 0.001 vs A&lt;</td>
<td>53 (16/30)</td>
<td>p &lt; 0.001 vs A&lt;</td>
</tr>
<tr>
<td>D</td>
<td>None</td>
<td>0 (0/30)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* Table 1

- A, B, C, and D correspond to the experimental groups.
- Ni₃S₂ is a 10 mg/injection site administered i.m. into both thighs.
- 3,4-Benzpyrene is a 5 mg/injection site administered i.m. into both thighs.
- Combination of Ni₃S₂ (10 mg/injection site) and 3,4-benzpyrene (5 mg/injection site) administered i.m. into both thighs.
- Vehicle (penicillin G procaine suspension, 150,000 units/0.5 ml) administered i.m. into both thighs.
- Probability based upon null hypothesis for differences between groups, computed by Yates’ x² test; N.S., not significant.

---

R. M. Maenza, A. M. Pradhan, F. W. Sunderman, Jr.
**Ni$_3$S$_2$-3,4-Benzpyrene Induction of Rat Sarcomas**

### Table 2

<table>
<thead>
<tr>
<th>Experimental group</th>
<th>Carcinogen</th>
<th>All sarcomas</th>
<th>Rhabdomyosarcomas</th>
<th>Fibrosarcomas</th>
<th>Weeks between injection of carcinogen and palpation of tumor at injection site$^d$</th>
<th>Weeks between injection of carcinogen and death</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Ni$_3$S$_2$ $^b$</td>
<td>$26 \pm 5$</td>
<td>$27 \pm 6$</td>
<td>$26 \pm 3$</td>
<td>$33 \pm 5$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$N = 42$</td>
<td>$N = 34$</td>
<td>$N = 8$</td>
<td>$N = 30$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$31 \pm 10$</td>
<td>$23 \pm 3$</td>
<td>$32 \pm 10$</td>
<td>$41 \pm 11$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$30 (17–54)$</td>
<td>(18–27)</td>
<td>(17–54)</td>
<td>(21–61)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$N = 39$</td>
<td>$N = 34$</td>
<td>$N = 30$</td>
<td>$N = 30$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$p &lt; 0.05$ vs. A$^e$</td>
<td>$p &lt; 0.05$ vs A</td>
<td>$p &lt; 0.01$ vs A</td>
<td>$p &lt; 0.01$ vs A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18 ± 3</td>
<td>19 ± 3</td>
<td>17 ± 2</td>
<td>24 ± 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$N = 46$</td>
<td>$N = 42$</td>
<td>$N = 4$</td>
<td>$N = 30$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$p &lt; 0.001$ vs. A</td>
<td>$p &lt; 0.001$ vs A</td>
<td>$p &lt; 0.001$ vs A</td>
<td>$p &lt; 0.001$ vs A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$p &lt; 0.001$ vs. B</td>
<td>$p &lt; 0.001$ vs B</td>
<td>$p &lt; 0.001$ vs B</td>
<td>$p &lt; 0.001$ vs B</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^a$ The values on the 1st line of each entry are the mean ± S.D.; the values on the 2nd line are the median and range; the number of items in each category is indicated on the 3rd line of each entry.

$^b$ Ni$_3$S$_2$ (10 mg/injection site) administered i.m. into both thighs.

$^c$ 3,4-Benzpyrene (5 mg/injection site) administered i.m. into both thighs.

$^d$ Combination of Ni$_3$S$_2$ (10 mg/injection site) and 3,4-benzpyrene (5 mg/injection site) administered i.m. into both thighs.

$^e$ Probability based upon null hypothesis for differences between means, computed by Student’s t test.

**DISCUSSION**

This study has shown that sarcomas induced in Fischer rats by bilateral i.m. injections of 5 mg of 3,4-benzpyrene (Group B) are predominantly fibrosarcomas and that sarcomas induced under identical conditions by 10 mg of Ni$_3$S$_2$ (Group A) or by the combination of 10 mg of Ni$_3$S$_2$ and 5 mg of 3,4-benzpyrene (Group C) are predominantly rhabdomyosarcomas. The mean latent period of the sarcomas produced by the combination of Ni$_3$S$_2$ and 3,4-benzpyrene (4.5 months) was 30% shorter than that observed with Ni$_3$S$_2$ (6.5 months). Such shortening of the latent period cannot be accomplished merely by increasing the dosage of Ni$_3$S$_2$. Thus, Gilman (7) has shown that the minimum latent period for induction of sarcomas by i.m. administration of Ni$_3$S$_2$ is achieved at a dosage of 2 mg of Ni$_3$S$_2$ per injection site and that no further diminution of latent period is achieved with dosages of Ni$_3$S$_2$, up to 20 mg per injection site.

From a theoretical viewpoint, this study furnishes support for speculations regarding carcinogenic interaction between nickel compounds and polycyclic aromatic hydrocarbons (4, 19, 22, 24, 25). Similar observations have been reported by Toda (27), who found that 5 of 30 rats (17%) that received intratracheal injection of nickel oxide in combination with 20-methylcholanthrene developed pulmonary neoplasms (squamous cell carcinomas), compared with no pulmonary neoplasms in rats that received only 20-methylcholanthrene.

From a practical viewpoint, this study furnishes an exceptionally rapid and convenient method for inducing sarcomas in rats. Based upon its use during the past 2 years in the curriculum for medical and dental students at the University of Connecticut, this technique is well suited as a laboratory exercise in pathology courses, as a means of demonstrating the induction of cancer. The particular advantages of this experimental method are as follows. (a) The technique is safe for student use, provided simple precautions are observed, such as use of disposable gloves, syringes, and needles. Accidental spillage and potential contamination with carcinogenic agents can be readily monitored by use of UV light to detect the fluorescence of 3,4-benzpyrene. (b) The carcinogens are administered parenterally in a single laboratory session, and no expensive laboratory equipment is needed. The rats can be housed in general animal quarters, without isolation precautions or special handling of excreta. (c) The mean latent period of 4.5 months permits a laboratory exercise in carcinogenesis to be initiated and the resulting tumors to be observed within the span of a single academic semester. (d) The relatively high incidence of distant tumor metastases permits the laboratory demonstration of an important facet of neoplastic disease to pathology students. (e) The sarcomas are readily transplantable, providing a source of neoplastic tissue for didactic and investigational purposes.

**ACKNOWLEDGMENTS**

We are grateful to Dr. John P. W. Gilman, Dr. Parvathi K. Basrur, Dr. Arthur Furst, and Dr. Marcus M. Mason for valuable advice and assistance; to Dr. Lewis J. Cralley for measurements of the mean particle diameters of the Ni$_3$S$_2$ and 3,4-benzpyrene powders and for emission spectrographic analysis of the Ni$_3$S$_2$; to Dr. Svend W. Nielsen, Dr. Peter B. Hukill, and Dr. Leonard Robinson for consultations regarding histological classification of the sarcomas; to Dr. Peter J.

**DECEMBER 1971**

2069
REFERENCES


Ni$_3$S$_2$-3,4-Benzpyrene Induction of Rat Sarcomas
Rapid Induction of Sarcomas in Rats by Combination of Nickel Sulfide and 3,4-Benzpyrene

Ronald M. Maenza, Arun M. Pradhan and F. William Sunderman, Jr.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/31/12/2067

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.